TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02960243

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Description: * DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: * DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: * DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: * DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well
Study: NCT03539588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point dry needling
Description: placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point dry needling
Description: placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
Study: NCT02241590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir + Placebo
Description: The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Fuzheng Huayu Tablet
Description: The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
Study: NCT02844634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100mg PO daily x 12 months
Description: Immediate use of daily doxycycline (12 months duration, to start immediately)
Study: NCT00194129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
Study: NCT02844634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/emtricitabine 200/300mg PO daily
Description: Daily use of tenofovir/emtricitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine 200/300mg PO daily
Description: Daily use of tenofovir/emtricitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100mg PO daily x 6 months
Description: Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
Study: NCT00867308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg
Study: NCT03337659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
Study: NCT05604001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hysteroscopic ablation of submucous uterine fibroid using diode laser
Description: patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma
Study: NCT04604561

Intervention type: DEVICE
Intervention: EnVisio SmartClip
Description: The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.

Intervention type: DEVICE
Intervention: EnVisio SmartClip
Description: The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.

Intervention type: DEVICE
Intervention: EnVisio SmartClip
Description: The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.

Intervention type: DEVICE
Intervention: EnVisio™ Navigation System
Description: The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.

Intervention type: DEVICE
Intervention: EnVisio™ Navigation System
Description: The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.

Intervention type: DEVICE
Intervention: EnVisio™ Navigation System
Description: The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
Study: NCT03831386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-Based IPC
Description: An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gravity-Based IPC
Description: An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
Study: NCT00194129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
Study: NCT02976311

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section(C/S) via the modified Misgav-Ladach technique
Description: the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section via the Pfannenstiel-Kerr technique
Description: the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
Study: NCT02068638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IHE first, CONT second
Description: IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CONT first, IHE second
Description: CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GLU first, GLU-FRU second
Description: : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GLU-FRU first, GLU second
Description: GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
Study: NCT01195779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2321138A
Description: Intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Intramuscular injections
Study: NCT03850717

Intervention type: DEVICE
Intervention: acupuncture
Description: insert in filiform needles into skin and other soft tissue to treat the illness or disorders

Intervention type: DEVICE
Intervention: acupuncture
Description: insert in filiform needles into skin and other soft tissue to treat the illness or disorders
Study: NCT01541709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
Study: NCT03980548

Intervention type: PROCEDURE
Intervention: CABG
Description: Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI

Intervention type: PROCEDURE
Intervention: CABG
Description: Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI

Intervention type: PROCEDURE
Intervention: CABG
Description: Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI

Intervention type: PROCEDURE
Intervention: CABG
Description: Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
Study: NCT03215069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg PO daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo PO daily
Study: NCT01401595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram oxalate
Description: The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
Study: NCT02990403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin

Intervention type: DRUG
Group type: OTHER
Intervention: Dydrogesterone
Study: NCT02148393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrification with subsequent-cycle embryo thawing/transfer
Description: The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensified luteal phase support for fresh embryo transfer
Description: A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl®
Description: 1500 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan®
Description: 200 mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progynova®
Description: 2 mg bid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBioSystem®
Description: CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
Study: NCT01507181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: single dose IV ketamine, .5mg/kg infused over 40 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: single dose IV midazolam, .45mg/kg infused over 40 minutes
Study: NCT02785393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: The administration of a sugar pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: The administration of the Doxazosin medication
Study: NCT03583957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Observational only
Description: Device is only observational and used to record EEG.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and Behavioral interaction with a seizure forecasting mobile app
Description: Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Seizure Alerting and Prediction System
Description: The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
Study: NCT00825123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 10 mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol 50 mg once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder
Study: NCT00368108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg perampanel
Description: 2 mg perampanel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg perampanel
Description: 4 mg perampanel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo comparator
Study: NCT01926028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-3A
Description: 0.5mL injection IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-3
Description: 0.5mL injection IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: aluminum hydroxide and buffered saline
Study: NCT03477578

Intervention type: OTHER
Intervention: freezers
Description: neuropsychological evaluation

Intervention type: OTHER
Intervention: freezers
Description: neuropsychological evaluation

Intervention type: OTHER
Intervention: non freezers
Description: neuropsychological evaluation

Intervention type: OTHER
Intervention: non freezers
Description: neuropsychological evaluation
Study: NCT02390154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roniciclib (BAY 1000394)
Description: Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of \[14C\] roniciclib solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roniciclib (BAY 1000394)
Description: 5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
Study: NCT02729337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITG (In This Together)
Description: Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
Study: NCT03675646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intrathecal injection of 250 mcg preservative-free morphine before surgery
Study: NCT03577249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialysis Solutions
Description: Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
Study: NCT00904475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidoderm®
Description: Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
Study: NCT04605900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthopedic Footwear
Description: The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Footwear
Description: In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plantar Orthoses
Description: The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plantar Orthoses
Description: The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on foot self-care
Description: An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on foot self-care
Description: An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal.